CELF5

Across TCGA pan-cancer cohorts, CELF5 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CELF5 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CELF5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CELF5 expression acts as an unfavorable survival marker.

LIHC are the cancer types where CELF5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.046	0.553	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

CELF5–LIHC (DFS)

Open the LIHC breakdown →